

Comparison of the Monovalent vs Bivalent COVID-19 Vaccine

10/18/2022



Moderna	Monovalent*	Monovalent*	Bivalent
Authorized Age	12 years +	6 thru 11 years	6 years +
Indication for use	Primary series doses	Primary series doses	Booster dose after completion of a primary series or last monovalent booster
Authorized dose (6-11 yrs)	N/A	50 mcg	25 mcg or 0.25ml
Authorized dose (12 yrs+)	100 mcg	N/A	50 mcg or 0.5ml
Dose (mRNA conc)	100 mcg/0.5ml	50 mcg/0.5ml	50 mcg/0.5ml
Vaccine composition	Monovalent - 100 mcg original	Monovalent - 50 mcg original	Bivalent - 25mcg original + 25mcg BA.4/BA.5 per 0.5ml

Pfizer-BioNTech	Monovalent*	Monovalent*	Bivalent	Bivalent
Authorized Age	12 years +	5 thru 11 years	12 years +	5 thru 11 years
Indication for use	Primary series doses	Primary series doses	Booster dose after completion of a primary series or last monovalent booster	Booster dose after completion of a primary series or last monovalent booster
Authorized dose	30 mcg	10 mcg	30 mcg	10 mcg
Dose (mRNA conc)	30 mcg/0.3 ml	10 mcg/0.2ml	30 mcg/0.3ml	10 mcg/0.2ml
Vaccine composition	Monovalent - 30 mcg original	Monovalent - 10 mcg original	Bivalent - 15mcg original + 15mcg BA.4/BA.5	Bivalent - 5mcg original + 5mcg BA.4/BA.5

* **NOTE:** other monovalent vaccine formulations exist for other younger age groups but not listed here.